NYU'S Duster cautions against FDA approval of 'race-based' phar...( New York University Sociologist Troy Du...),Health

New York University Sociologist Troy Duster concludes that a pharmaceutical to combat heart disease among blacks is based on faulty research and urges the Food and Drug Administration to obtain more reliable data before approving the drug. Duster, president of the American Sociological Association, writes that research on isosorbide dinitrate and hydralazine (BiDil), produced by NitroMed, incorrectly links a biological idea of race to heart disease and that socioeconomic factors better explain susceptibility to heart disease. Duster's analysis appears in Science magazine.

"Race is such a dominant category in the cognitive field that it can leave its own indelible mark once given even the temporary imprimatur of scientific legitimacy by molecular genetics," Duster writes, expressing concern for the precedent the NitroMed study may set.

However, Duster encourages continued research to match genetics and medical treatment.

"An increased understanding of genetic diversity will help scientists doing gene-association studies by identifying new variants and reducing the likelihood of false-positive associations," he writes. "The hope is that it may aid scientists to identify medically relevant genes for diseases."

Initially, the FDA rejected its use to treat heart disease because of its ineffectiveness among the general population. However, the company began testing BiDil exclusively on blacks with FDA approvalafter theorizing that the drug's effect on nitric-oxide deficiency, which is more common in black heart-failure patients than in non-blacks, would be beneficial to a targeted racial population. NitroMed reported effectiveness of the BiDil in its clinical trial of 400 black women and 600 black men.

NitroMed, which intends to market the drug to African Americans after FDA approval, has noted that African Americans between the ages of 45 and 64 are two-and-a-half times more likely to die from hear
'"/>

Contact: James Devitt
james.devitt@nyu.edu
212-998-6808
New York University
25-Feb-2005

Page: 1 2
Related medicine news :

1. Strategy effective against drug resistant tuberculosis
2. New study in Nature demonstrates protection against cell death during heart attack
3. Vaccine against childhood pneumonia shows promise
4. Mayo Clinic discovers new pathway against pancreatic cancer
5. Orthodontists must brace against back pain
6. Female sex hormones play a vital role in defense against sexually transmitted diseases
7. New European cancer figures for 2004 major efforts needed against the big four killers
8. New highly active agents against sandfly fever
9. New mosquito control strategy proves successful against dengue fever
10. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
11. Gene vaccine protects mice against development of Her2/neu breast cancer